Company
Headquarters: Zhengzhou, China
CN¥3.46 Billion
CNY as of Jan. 1, 2024
US$486.8 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Henan Taloph Pharmaceutical Stock Co., Ltd. researches, produces, and sells Chinese and western medicines in China. It primarily offers its products in the forms of oral liquids, tablets, capsules, fluids, and other forms. The company's principal products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, pazufloxacin mesylate sodium chloride injections, and various infusion products. It serves hospitals, pharmacies, and patients. The company was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. is based in Zhengzhou, China.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Henan Taloph Pharmaceutical Stock Co.,Ltd has the following listings and related stock indices.
Stock: SSE: 600222 wb_incandescent